EB, 74, with HFrEF, started spironolactone 12.5 mg daily 1 week ago alongside sacubitril/valsartan. Today potassium is 5.8 mmol/L (previously 4.6) and creatinine has risen 15%. Which of the following is the most appropriate action?
Hyperkalemia is the main risk of MRAs, especially in older adults on RAS inhibitors. Heart failure guidance and the spironolactone monograph advise holding the MRA when potassium exceeds about 5.5 mmol/L and reassessing; once potassium normalises, a lower dose or alternate-day dosing may be retried. Increasing the dose or adding dietary potassium is dangerous, and permanently stopping the ARNI removes a key mortality-reducing therapy. Source: CCS/CHFS HF guidelines (Ezekowitz JA et al. Can J Cardiol 2017;33:1342 and 2021 update), MRA monitoring; spironolactone product monograph, Warnings: hyperkalemia (DPD, checked 2026).
Continuing an MRA through significant hyperkalemia.
Practice more PEBC MCQ Heart Failure, AF, CAD & Anticoagulation questions
Exam-style questions with worked answers, then full timed mocks. Free to start.
Build a daily practice habit — a few exam-style questions a day, with worked answers. Free to start.
Start practicing →Original practice material written to the public PEBC blueprint; not a past or real exam question. Not affiliated with or endorsed by The Pharmacy Examining Board of Canada (PEBC). Educational practice material for exam preparation only. Not medical advice and not a substitute for current product monographs, clinical guidelines or professional judgement. Questions have not yet been reviewed by a licensed pharmacist.